CN113332161A - 一种甘草酸铵水凝胶及其制备方法和应用 - Google Patents
一种甘草酸铵水凝胶及其制备方法和应用 Download PDFInfo
- Publication number
- CN113332161A CN113332161A CN202110376489.2A CN202110376489A CN113332161A CN 113332161 A CN113332161 A CN 113332161A CN 202110376489 A CN202110376489 A CN 202110376489A CN 113332161 A CN113332161 A CN 113332161A
- Authority
- CN
- China
- Prior art keywords
- glycyrrhizinate
- hydrogel
- ethanol
- ammonium
- skin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000017 hydrogel Substances 0.000 title claims abstract description 44
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 50
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 claims abstract description 28
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960004949 glycyrrhizic acid Drugs 0.000 claims abstract description 28
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000001685 glycyrrhizic acid Substances 0.000 claims abstract description 28
- 235000019410 glycyrrhizin Nutrition 0.000 claims abstract description 28
- 229940088597 hormone Drugs 0.000 claims abstract description 15
- 239000005556 hormone Substances 0.000 claims abstract description 15
- 150000003839 salts Chemical class 0.000 claims abstract description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 11
- 201000004624 Dermatitis Diseases 0.000 claims abstract description 10
- 230000001419 dependent effect Effects 0.000 claims abstract description 10
- 230000037307 sensitive skin Effects 0.000 claims abstract description 8
- 229920005862 polyol Polymers 0.000 claims abstract description 7
- 150000003077 polyols Chemical class 0.000 claims abstract description 7
- 238000002657 hormone replacement therapy Methods 0.000 claims abstract description 6
- 230000000699 topical effect Effects 0.000 claims abstract description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 28
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 15
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 14
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 14
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 14
- 239000000203 mixture Substances 0.000 claims description 13
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 9
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims description 9
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 9
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims description 9
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 claims description 9
- 229920002674 hyaluronan Polymers 0.000 claims description 9
- 229960003160 hyaluronic acid Drugs 0.000 claims description 9
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 8
- 238000003756 stirring Methods 0.000 claims description 7
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 6
- RADKZDMFGJYCBB-UHFFFAOYSA-N Pyridoxal Chemical compound CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 6
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 6
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 claims description 6
- WERYXYBDKMZEQL-UHFFFAOYSA-N butane-1,4-diol Chemical compound OCCCCO WERYXYBDKMZEQL-UHFFFAOYSA-N 0.000 claims description 6
- ZSIAUFGUXNUGDI-UHFFFAOYSA-N hexan-1-ol Chemical compound CCCCCCO ZSIAUFGUXNUGDI-UHFFFAOYSA-N 0.000 claims description 6
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 claims description 6
- 229910052700 potassium Inorganic materials 0.000 claims description 6
- 239000011591 potassium Substances 0.000 claims description 6
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims description 5
- 229960003720 enoxolone Drugs 0.000 claims description 5
- 229940074774 glycyrrhizinate Drugs 0.000 claims description 5
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 claims description 4
- 241000202807 Glycyrrhiza Species 0.000 claims description 4
- -1 Glycyrrhiza flavonoids Chemical class 0.000 claims description 4
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 4
- 238000001816 cooling Methods 0.000 claims description 4
- 229920006037 cross link polymer Polymers 0.000 claims description 4
- 229940072008 glycyrrhiza glabra extract Drugs 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 4
- 229960000367 inositol Drugs 0.000 claims description 4
- 229940101267 panthenol Drugs 0.000 claims description 4
- 235000020957 pantothenol Nutrition 0.000 claims description 4
- 239000011619 pantothenol Substances 0.000 claims description 4
- 235000008160 pyridoxine Nutrition 0.000 claims description 4
- 239000011677 pyridoxine Substances 0.000 claims description 4
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims description 4
- 150000005846 sugar alcohols Polymers 0.000 claims description 4
- 229940011671 vitamin b6 Drugs 0.000 claims description 4
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 claims description 3
- CAKDFKUXFMLCAR-UIOGXPPZSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-methoxycarbonyl-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@]([C@@]3(CC[C@H]2C1(C)C)C)(C)CC[C@@]1(C)CC[C@](C[C@H]14)(C)C(=O)OC)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O CAKDFKUXFMLCAR-UIOGXPPZSA-N 0.000 claims description 3
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 claims description 3
- MPDGHEJMBKOTSU-WFJWTYAKSA-N (2s,4as,6as,6br,10s,12as)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid Chemical compound C12C(=O)C=C3C4C[C@@](C)(C(O)=O)CC[C@]4(C)CC[C@@]3(C)[C@]1(C)CCC1[C@]2(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-WFJWTYAKSA-N 0.000 claims description 3
- 229940083957 1,2-butanediol Drugs 0.000 claims description 3
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 3
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 claims description 3
- 229940035437 1,3-propanediol Drugs 0.000 claims description 3
- 229940043375 1,5-pentanediol Drugs 0.000 claims description 3
- ALVZNPYWJMLXKV-UHFFFAOYSA-N 1,9-Nonanediol Chemical compound OCCCCCCCCCO ALVZNPYWJMLXKV-UHFFFAOYSA-N 0.000 claims description 3
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 claims description 3
- MSHFRERJPWKJFX-UHFFFAOYSA-N 4-Methoxybenzyl alcohol Chemical compound COC1=CC=C(CO)C=C1 MSHFRERJPWKJFX-UHFFFAOYSA-N 0.000 claims description 3
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 3
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 claims description 3
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- KPQJOKRSYYJJEL-VLQRKCJKSA-K [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O Chemical compound [Na+].[Na+].CC1(C)[C@H](CC[C@@]2(C)[C@H]1CC[C@]1(C)[C@@H]2C(=O)C=C2[C@@H]3C[C@](C)(CC[C@]3(C)CC[C@@]12C)C([O-])=O)O[C@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O[C@@H]1O[C@@H]([C@@H](O)[C@H](O)[C@H]1O)C([O-])=O)C([O-])=O KPQJOKRSYYJJEL-VLQRKCJKSA-K 0.000 claims description 3
- 235000010323 ascorbic acid Nutrition 0.000 claims description 3
- 229960005070 ascorbic acid Drugs 0.000 claims description 3
- 239000011668 ascorbic acid Substances 0.000 claims description 3
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 3
- BMRWNKZVCUKKSR-UHFFFAOYSA-N butane-1,2-diol Chemical compound CCC(O)CO BMRWNKZVCUKKSR-UHFFFAOYSA-N 0.000 claims description 3
- OWBTYPJTUOEWEK-UHFFFAOYSA-N butane-2,3-diol Chemical compound CC(O)C(C)O OWBTYPJTUOEWEK-UHFFFAOYSA-N 0.000 claims description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 3
- 229940075894 denatured ethanol Drugs 0.000 claims description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 claims description 3
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 claims description 3
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 3
- XXMIOPMDWAUFGU-UHFFFAOYSA-N hexane-1,6-diol Chemical compound OCCCCCCO XXMIOPMDWAUFGU-UHFFFAOYSA-N 0.000 claims description 3
- 229940014041 hyaluronate Drugs 0.000 claims description 3
- 239000000832 lactitol Substances 0.000 claims description 3
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 claims description 3
- 235000010448 lactitol Nutrition 0.000 claims description 3
- 229960003451 lactitol Drugs 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- FVXBCDWMKCEPCL-UHFFFAOYSA-N nonane-1,1-diol Chemical compound CCCCCCCCC(O)O FVXBCDWMKCEPCL-UHFFFAOYSA-N 0.000 claims description 3
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 3
- WNIFXKPDILJURQ-JKPOUOEOSA-N octadecyl (2s,4as,6ar,6as,6br,8ar,10s,12as,14br)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1h-picene-2-carboxylate Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@](C(=O)OCCCCCCCCCCCCCCCCCC)(C)C[C@H]5C4=CC(=O)[C@@H]3[C@]21C WNIFXKPDILJURQ-JKPOUOEOSA-N 0.000 claims description 3
- OEIJHBUUFURJLI-UHFFFAOYSA-N octane-1,8-diol Chemical compound OCCCCCCCCO OEIJHBUUFURJLI-UHFFFAOYSA-N 0.000 claims description 3
- UWJJYHHHVWZFEP-UHFFFAOYSA-N pentane-1,1-diol Chemical compound CCCCC(O)O UWJJYHHHVWZFEP-UHFFFAOYSA-N 0.000 claims description 3
- 229920000166 polytrimethylene carbonate Polymers 0.000 claims description 3
- 229960003975 potassium Drugs 0.000 claims description 3
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 3
- 235000008164 pyridoxal Nutrition 0.000 claims description 3
- 239000011674 pyridoxal Substances 0.000 claims description 3
- 229960003581 pyridoxal Drugs 0.000 claims description 3
- 235000020945 retinal Nutrition 0.000 claims description 3
- 239000011604 retinal Substances 0.000 claims description 3
- 230000002207 retinal effect Effects 0.000 claims description 3
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 claims description 3
- 229960003471 retinol Drugs 0.000 claims description 3
- 235000020944 retinol Nutrition 0.000 claims description 3
- 239000011607 retinol Substances 0.000 claims description 3
- WWDMJSSVVPXVSV-YCNIQYBTSA-N retinyl ester Chemical compound CC1CCCC(C)(C)C1\C=C\C(\C)=C\C=C\C(\C)=C\C(O)=O WWDMJSSVVPXVSV-YCNIQYBTSA-N 0.000 claims description 3
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims description 3
- 229960001295 tocopherol Drugs 0.000 claims description 3
- 235000010384 tocopherol Nutrition 0.000 claims description 3
- 229930003799 tocopherol Natural products 0.000 claims description 3
- 239000011732 tocopherol Substances 0.000 claims description 3
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 claims description 3
- CCXAYLQLOLXXKE-DWJAGBRCSA-K trisodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4s,5s,6s)-2-[[(3s,4ar,6ar,6bs,8as,11s,12ar,14ar,14bs)-11-carboxylato-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1h-picen-3-yl]oxy]-6-carboxylato-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-t Chemical compound [Na+].[Na+].[Na+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C([O-])=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O CCXAYLQLOLXXKE-DWJAGBRCSA-K 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 239000011701 zinc Substances 0.000 claims description 3
- 229910052725 zinc Inorganic materials 0.000 claims description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 claims description 3
- 229930003935 flavonoid Natural products 0.000 claims description 2
- 235000017173 flavonoids Nutrition 0.000 claims description 2
- LTINPJMVDKPJJI-UHFFFAOYSA-N iodinated glycerol Chemical compound CC(I)C1OCC(CO)O1 LTINPJMVDKPJJI-UHFFFAOYSA-N 0.000 claims description 2
- 230000008569 process Effects 0.000 claims description 2
- RWLALWYNXFYRGW-UHFFFAOYSA-N 2-Ethyl-1,3-hexanediol Chemical compound CCCC(O)C(CC)CO RWLALWYNXFYRGW-UHFFFAOYSA-N 0.000 claims 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims 1
- 229960005082 etohexadiol Drugs 0.000 claims 1
- 229960003966 nicotinamide Drugs 0.000 claims 1
- 235000005152 nicotinamide Nutrition 0.000 claims 1
- 239000011570 nicotinamide Substances 0.000 claims 1
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 5
- 239000000499 gel Substances 0.000 description 7
- 208000003251 Pruritus Diseases 0.000 description 4
- 230000007803 itching Effects 0.000 description 4
- 238000001338 self-assembly Methods 0.000 description 4
- 206010015150 Erythema Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- DFPAKSUCGFBDDF-ZQBYOMGUSA-N [14c]-nicotinamide Chemical compound N[14C](=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-ZQBYOMGUSA-N 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 125000004080 3-carboxypropanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C(O[H])=O 0.000 description 2
- TXFPEBPIARQUIG-UHFFFAOYSA-N 4'-hydroxyacetophenone Chemical compound CC(=O)C1=CC=C(O)C=C1 TXFPEBPIARQUIG-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022535 Infectious Skin disease Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- 206010040799 Skin atrophy Diseases 0.000 description 1
- 206010043189 Telangiectasia Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 208000037896 autoimmune cutaneous disease Diseases 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 230000036561 sun exposure Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 208000009056 telangiectasis Diseases 0.000 description 1
- 238000000870 ultraviolet spectroscopy Methods 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/63—Steroids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/042—Gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/005—Preparations for sensitive skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
Abstract
本发明公开了一种甘草酸铵水凝胶及其制备方法和应用,属于化妆品领域,包括以下质量百分比的组分:甘草酸及其盐0.001wt%~15wt%、多元醇0.001wt%~50wt%、水50wt%~90wt%,且所有组分用量总和为100%。本发明具有自组装水凝胶的特征,解决了甘草酸铵溶解度低和添加量不足而难以发挥生物学功效的问题。用于涂抹在皮肤表面,改善皮肤状态和外观,舒缓敏感性皮肤,用于激素依赖性皮炎的基础护理,更特别地用于局部激素替代疗法。
Description
技术领域
本发明属于化妆品领域,具体涉及一种甘草酸铵水凝胶及其制备方法和应用。
背景技术
敏感性皮肤已成为世界性难题,有超过一半的人宣称有皮肤敏感问题困扰,主要表现为灼热、泛红、刺痛、瘙痒、紧绷,传统碱性清洁剂与护肤品被认为是敏感性皮肤的主要因素。
激素依赖性皮炎是长期使用激素或含激素的劣质化妆品而反复出现的皮肤泛红、灼热、刺痛、瘙痒、干燥、紧绷,伴有皮肤萎缩与毛细血管扩张。临床上主要以激素递减、替代疗法来缓解症状。
天然植物研究一直是全球化妆品与个人护理品产业的热点。研究表明,甘草提取物甘草酸及其衍生物具有抗炎、抗病毒和免疫调节作用,广泛用于感染性皮肤性病、炎症与***反应性皮肤病、自身免疫性皮肤病等领域,效果与皮质激素相当,同时避免了皮质激素的严重不良反应。皮肤外用甘草酸类的挑战是溶解度低和生物利用度低,现有的技术是通过增溶或包裹以提高溶解性,活性物的含量较低。
因此,需开发一种新型甘草酸类制剂来提高甘草酸类的生物利用度和皮肤功效。
发明内容
本发明的目的在于提供一种甘草酸铵水凝胶及其制备方法和应用,利用甘草酸类分子在水溶液中的自组装凝胶特性,以解决如何提高甘草酸制剂的活性物浓度、皮肤靶向性和生物利用度,而充分发挥其生物学功效的问题。
为实现本发明目的,采用的技术方案为:一种甘草酸铵水凝胶,包括以下质量百分比的组分:甘草酸及其盐0.001wt%~15wt%、多元醇0.001wt%~50wt%、水50wt%~90wt%,且所有组分用量总和为100%。
作为进一步可选方案,所述甘草酸及其盐的质量百分比为0.5wt%~5wt%。
作为进一步可选方案,所述甘草酸及其盐、多元醇的重量比为20:1~1:20。
作为进一步可选方案,所述甘草酸及其盐选自甘草酸、甘草酸铵、甘草酸二钾、甘草酸二钠、甘草酸钾、甘草酸三钠、甘草亭酸、甘草亭酸锌、甘草亭酸硬脂酸酯、光果甘草提取物、琥珀酰甘草亭酸二钠、硬脂醇甘草亭酸酯、甘油甘草亭酸酯、甘草酸甲酯、甘草提取物、甘草类黄酮中的任一种。
作为进一步可选方案,所述多元醇选自丙醇、异丙醇、丙二醇、1,3-丙二醇、二丙二醇、甘油、双甘油、丁二醇、1,2-丁二醇、1,4-丁二醇、2,3-丁二醇、戊二醇、1,2-戊二醇、1,5-戊二醇、叔丁醇、木糖醇、茴香醇、二甘醇、三甘醇、己醇、1,2-己二醇、1,6-己二醇、壬二醇、1,9-壬二醇、乳糖醇、辛二醇、辛甘醇、乙醇、乙二醇、SD乙醇-38B、SD乙醇-38C、SD乙醇-39C、SD 乙醇40、SD乙醇40-A、SD乙醇40-B、变性乙醇中的任一种或几种组合。
作为进一步可选方案,其组分还包括但不限于:视黄酯、视黄醇、视黄醛、烟酰胺、泛醇、吡哆素、吡哆醛、抗坏血酸、生育酚、肌醇中的任一种或几种组合。
作为进一步可选方案,其组分还包括透明质酸及其衍生物,所述透明质酸及其衍生物选自:透明质酸、透明质酸钠、透明质酸钾、水解透明质酸、水解透明质酸钠、透明质酸钠交联聚合物、乙酰化透明质酸钠中的一种或几种组合。
本发明还提供一种如上任一项所述水凝胶的制备方法,包括如下步骤:
1)按质量比称取各组分;
2)将各组分逐一加入水相锅并充分搅拌;
3)加热搅拌至完全溶解;
4)静置、冷却、凝胶化。
本发明还提供所述水凝胶用于改善皮肤状态和外观,或用于舒缓敏感性皮肤。
作为进一步可选方案,用于激素依赖性皮炎的护理或用于局部激素替代疗法。
本发明的有益效果是:
1、本发明的水凝胶,可显著增加甘草酸及其盐的溶解度,有效实现皮肤靶向递送,从而提高甘草酸及其盐的生物利用度和皮肤功效。
2、本发明的水凝胶,用于涂抹在皮肤表面,改善皮肤状态和外观,舒缓敏感性皮肤,用于激素依赖性皮炎的基础护理,更特别地用于皮质激素替代疗法。
3、本发明的水凝胶,采用加热搅拌溶解然后在静置冷却中使小分子晶体自组装形成水凝胶,生产工艺易于控制。
4、本发明的水凝胶,具有热触变性,在常温及较低的温度下呈凝胶状态,加热后呈液态,反复加热后质量稳定。
5、本发明的水凝胶,具有对酸碱和电解质稳定的特性,可以在更宽的pH 范围内制成与皮肤生理pH值相适应的个人护理产品。
附图说明
为了更清楚地说明本发明的技术方案,下面将对实施例描述中所需要使用的附图作简单地介绍,应当理解的是,下面描述中的附图是本发明的一些实施例,对于本领域普通技术人员来讲,在不付出创造性劳动的前提下,还可以根据这些附图获得其他的附图。
图1是本发明实施例提供的甘草酸铵水凝胶自组装示意图;
图2是采用本发明的甘草酸铵水凝胶用于激素依赖性皮炎过程中使用前和四周后的照片对比图。
具体实施方式
下面将结合本发明实施例中的附图,对本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明的实施例,本领域普通技术人员在没有做出创造性劳动的前提下所获得所有其他实施例,都属于本发明的保护范围。可以理解的是,附图仅仅提供参考与说明用,并非用来对本发明加以限制。
除非另有定义,本文所使用的所有的技术和科学术语与属于本发明的技术领域的技术人员通常理解的含义相同。本文中在本发明的说明书中所使用的术语只是为了描述具体的实施例的目的,不是旨在于限制本发明。
下面结合附图及具体实施例对本发明作进一步阐述。
本发明提供的水凝胶,包括以下质量百分比的组分:甘草酸及其盐 0.001wt%~15wt%、多元醇0.001wt%~50wt%、水50wt%~90wt%,且所有组分用量总和为100%。
其中,甘草酸及其盐的质量百分比为可优选0.5wt%~5wt%。
甘草酸及其盐、多元醇的重量比可优选20:1~1:20。
甘草酸及其盐选自甘草酸、甘草酸铵、甘草酸二钾、甘草酸二钠、甘草酸钾、甘草酸三钠、甘草亭酸、甘草亭酸锌、甘草亭酸硬脂酸酯、光果甘草提取物、琥珀酰甘草亭酸二钠、硬脂醇甘草亭酸酯、甘油甘草亭酸酯、甘草酸甲酯、甘草提取物、甘草类黄酮中的任一种。
多元醇选自丙醇、异丙醇、丙二醇、1,3-丙二醇、二丙二醇、甘油、双甘油、丁二醇、1,2-丁二醇、1,4-丁二醇、2,3-丁二醇、戊二醇、1,2-戊二醇、 1,5-戊二醇、叔丁醇、木糖醇、茴香醇、二甘醇、三甘醇、己醇、1,2-己二醇、 1,6-己二醇、壬二醇、1,9-壬二醇、乳糖醇、辛二醇、辛甘醇、乙醇、乙二醇、 SD乙醇-38B、SD乙醇-38C、SD乙醇-39C、SD乙醇40、SD乙醇40-A、SD乙醇 40-B、变性乙醇中的任一种或几种组合。
其组分还包括但不限于:视黄酯、视黄醇、视黄醛、烟酰胺、泛醇、吡哆素、吡哆醛、抗坏血酸、生育酚、肌醇中的任一种或几种组合。作为皮肤美容调理活性成分。
作为进一步可选方案,其组分还包括透明质酸及其衍生物,所述透明质酸及其衍生物选自:透明质酸、透明质酸钠、透明质酸钾、水解透明质酸、水解透明质酸钠、透明质酸钠交联聚合物、乙酰化透明质酸钠中的一种或几种组合。
本水凝胶的成分可根据与其它成分的平衡来适当设定,尤其通过调整甘草酸及其盐与多元醇的比例制成所需的水凝胶。可根据需要制成精华液或凝胶,制成的水凝胶同时具有热触变性,即在室温下呈稳定的凝胶状态,50℃以上时成液态。与现有技术相比具有更高的活性成分添加量、更好的稳定性,有效实现皮肤靶向递送,从而提高甘草酸的生物利用度和生物学功效。
实施例1
本实施例的水凝胶各组分如下:甘草酸铵1wt%、1,2-戊二醇5wt%、水94wt%。可用作舒敏水凝胶的制备。
实施例2
本实施例的水凝胶各组分如下:甘草酸铵2wt%、1,2-戊二醇5wt%、烟酰胺0.5wt%、吡哆素0.5wt%、泛醇0.5wt%、肌醇0.5wt%、透明质酸钠交联聚合物3wt%、水88wt%。可用作脂溢性皮炎基础护理水凝胶的制备。
实施例3
本实施例的水凝胶各组分如下:甘草酸铵3wt%、二丙二醇3wt%、1,2-戊二醇3wt%、对羟基苯乙酮0.5wt%、水解透明质酸钠1wt%、水89.5wt%。可用作激素依赖性皮炎局部激素替代疗法的水凝胶的制备。
一、水凝胶稳定性实验:
通过调节甘草酸铵与二丙二醇的比例来控制水凝胶的状态和稳定性,见下表。甘草酸铵水凝胶自组装示意图见图1。
甘草酸铵/二丙二醇 | 1:1 | 1:5 | 1:10 | 1:15 | 1:20 | 1:25 | 1:30 |
凝胶化 | 3 | 3 | 2 | 1 | 1 | 0 | 0 |
实验发现,当甘草酸铵与二丙二醇的重量比为1:25至1:30时,该组合物在室温下无法形成自组装凝胶而呈水状;当甘草酸铵与二丙二醇的重量比为1:1 至1:20时在室温下可以自组装形成凝胶,甘草酸铵与二丙二醇的重量比为1:1 至1:5时可形成更稳定的凝胶。
二、水凝胶体外甘草酸铵释放度测定:
通过微孔半透膜过滤和分光光度法在258nm波长处测定吸收度,测定体外药物释放度。仪器采用紫外扫描仪(UV-2201)和752型紫外可见分工光度仪。
时间(小时) | 0 | 1 | 4 | 6 |
累计释放度% | 75.50 | 79.56 | 85.34 | 89.78 |
体外释放实验发现,该水凝胶在涂抹在皮肤表面后可迅速释放,且有一定的缓释效应并持续释放至6小时以上。
三、效果评价:
5名研究人员,年龄18~35岁,自我感觉皮肤敏感,有轻度两颊泛红和瘙痒,无大量日晒史、无光感性疾病史。每日早晚洗脸后全脸涂抹本品,4周后均报告有改善。其中一例激素依赖性皮炎使用前和四周后的照片见图2。
本实施例还提供一种上述水凝胶的制备方法,包括如下步骤:
1)按质量比称取各组分;
2)将各组分逐一加入水相锅并充分搅拌;
3)加热搅拌至完全溶解;
4)静置、冷却、凝胶化。
本发明还提供所述水凝胶在激素依赖性皮炎护理中的应用。用于涂抹在皮肤表面,改善皮肤状态和外观,舒缓敏感性皮肤。改善皮肤状态和外观包括能够减轻皮肤光损伤和光老化的痕迹,改善皮肤屏障功能。舒缓敏感性皮肤包括能够缓解皮肤灼热、刺痛、瘙痒、泛红、干燥和紧绷。用于激素依赖性皮炎的基础护理,更特别地用于局部激素替代疗法。
与现有技术相比,本发明具有更高的甘草酸及其盐添加量、更好的稳定性,有效实现皮肤靶向递送,从而提高甘草酸铵的生物利用度和生物学功效。
本发明不局限于上述可选实施方式,任何人在本发明的启示下都可得出其他各种形式的产品,但不论在其形状或结构上作任何变化,凡是落入本发明权利要求界定范围内的技术方案,均落在本发明的保护范围之内。
Claims (10)
1.一种甘草酸铵水凝胶,其特征在于,包括以下质量百分比的组分:甘草酸及其盐0.001wt%~15wt%、多元醇0.001wt%~50wt%、水50wt%~90wt%,且所有组分用量总和为100%。
2.根据权利要求1所述的甘草酸铵水凝胶,其特征在于,所述甘草酸及其盐的质量百分比为0.5wt%~5wt%。
3.根据权利要求1所述的甘草酸铵水凝胶,其特征在于,所述甘草酸及其盐、多元醇的重量比为20:1~1:20。
4.根据权利要求1所述的甘草酸铵水凝胶,其特征在于,所述甘草酸及其盐选自甘草酸、甘草酸铵、甘草酸二钾、甘草酸二钠、甘草酸钾、甘草酸三钠、甘草亭酸、甘草亭酸锌、甘草亭酸硬脂酸酯、光果甘草提取物、琥珀酰甘草亭酸二钠、硬脂醇甘草亭酸酯、甘油甘草亭酸酯、甘草酸甲酯、甘草提取物、甘草类黄酮中的任一种。
5.根据权利要求1所述的甘草酸铵水凝胶,其特征在于,所述多元醇选自丙醇、异丙醇、丙二醇、1,3-丙二醇、二丙二醇、甘油、双甘油、丁二醇、1,2-丁二醇、1,4-丁二醇、2,3-丁二醇、戊二醇、1,2-戊二醇、1,5-戊二醇、叔丁醇、木糖醇、茴香醇、二甘醇、三甘醇、己醇、1,2-己二醇、1,6-己二醇、壬二醇、1,9-壬二醇、乳糖醇、辛二醇、辛甘醇、乙醇、乙二醇、SD乙醇-38B、SD乙醇-38C、SD乙醇-39C、SD乙醇40、SD乙醇40-A、SD乙醇40-B、变性乙醇中的任一种或几种组合。
6.根据权利要求1所述的甘草酸铵水凝胶,其特征在于,其组分还包括视黄酯、视黄醇、视黄醛、烟酰胺、泛醇、吡哆素、吡哆醛、抗坏血酸、生育酚、肌醇中的任一种或几种组合。
7.根据权利要求6所述的甘草酸铵水凝胶,其特征在于,其组分还包括透明质酸及其衍生物,所述透明质酸及其衍生物选自:透明质酸、透明质酸钠、透明质酸钾、水解透明质酸、水解透明质酸钠、透明质酸钠交联聚合物、乙酰化透明质酸钠中的一种或几种组合。
8.一种如权利要求1-7中任一项所述水凝胶的制备方法,其特征在于,包括如下步骤:
1)按质量比称取各组分;
2)将各组分逐一加入水相锅并充分搅拌;
3)加热搅拌至完全溶解;
4)静置、冷却、凝胶化。
9.一种如权利要求1-7中任一项所述水凝胶的应用,其特征在于,用于改善皮肤状态和外观,或用于舒缓敏感性皮肤。
10.根据权利要求9所述的应用,其特征在于,用于激素依赖性皮炎的护理或用于局部激素替代疗法。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110376489.2A CN113332161A (zh) | 2021-04-06 | 2021-04-06 | 一种甘草酸铵水凝胶及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110376489.2A CN113332161A (zh) | 2021-04-06 | 2021-04-06 | 一种甘草酸铵水凝胶及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN113332161A true CN113332161A (zh) | 2021-09-03 |
Family
ID=77467949
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110376489.2A Pending CN113332161A (zh) | 2021-04-06 | 2021-04-06 | 一种甘草酸铵水凝胶及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113332161A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115845125A (zh) * | 2022-12-07 | 2023-03-28 | 中南大学湘雅医院 | 一种负载色氨酸碳量子点的甘草酸水凝胶及其制备方法和应用 |
CN117180121A (zh) * | 2023-10-18 | 2023-12-08 | 广州品域美妆创新科技有限公司 | 一种含玻色因的抗皱淡纹组合物及其应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06279265A (ja) * | 1993-03-29 | 1994-10-04 | Shiseido Co Ltd | 透明ゲル組成物 |
CN102784095A (zh) * | 2011-05-17 | 2012-11-21 | 中国科学院理化技术研究所 | 甘草次酸水凝胶制剂及其制备方法和应用 |
EP2633887A1 (de) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Neuartige Wirkstoffkombination zur effizienten Anti-Faltenwirkung |
-
2021
- 2021-04-06 CN CN202110376489.2A patent/CN113332161A/zh active Pending
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH06279265A (ja) * | 1993-03-29 | 1994-10-04 | Shiseido Co Ltd | 透明ゲル組成物 |
CN102784095A (zh) * | 2011-05-17 | 2012-11-21 | 中国科学院理化技术研究所 | 甘草次酸水凝胶制剂及其制备方法和应用 |
EP2633887A1 (de) * | 2011-11-29 | 2013-09-04 | Henkel AG&Co. KGAA | Neuartige Wirkstoffkombination zur effizienten Anti-Faltenwirkung |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115845125A (zh) * | 2022-12-07 | 2023-03-28 | 中南大学湘雅医院 | 一种负载色氨酸碳量子点的甘草酸水凝胶及其制备方法和应用 |
CN115845125B (zh) * | 2022-12-07 | 2024-02-20 | 中南大学湘雅医院 | 一种负载色氨酸碳量子点的甘草酸水凝胶及其制备方法和应用 |
CN117180121A (zh) * | 2023-10-18 | 2023-12-08 | 广州品域美妆创新科技有限公司 | 一种含玻色因的抗皱淡纹组合物及其应用 |
CN117180121B (zh) * | 2023-10-18 | 2024-07-05 | 广州品域美妆创新科技有限公司 | 一种含玻色因的抗皱淡纹组合物及其应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105769698B (zh) | 一种不含防腐剂的化妆品组合物及其应用 | |
CN107137760B (zh) | 一种保湿修护敷料及其制备方法 | |
CN103585097B (zh) | 一种白及多糖载表皮生长因子复合物及其制备方法和应用 | |
CN113332161A (zh) | 一种甘草酸铵水凝胶及其制备方法和应用 | |
CN109549893A (zh) | 一种具有抗蓝光污染和修复功效的组合物和精华乳及其精华乳的制备方法 | |
WO2022105225A1 (zh) | 壬二酸凝胶剂及其制备方法和应用 | |
CN107362108A (zh) | 一种金花葵面膜及其制备方法 | |
CN104887542B (zh) | 一种化妆品组合物 | |
CN112656709A (zh) | 皮肤护理组合物及其应用 | |
CN113599391A (zh) | 羧甲基壳聚糖用于促进皮肤伤口愈合、修复皮肤屏障的用途 | |
CN109381348B (zh) | 一种稳定的高含量胶原蛋白透明化妆水 | |
CN106798656B (zh) | 一种包含牦牛骨小分子肽的深度养发素及其制备方法 | |
CN106236676B (zh) | 一种具有抗衰老功效的植物组合物及其应用 | |
CN109172422B (zh) | 一种透明质酸面膜液及其制备方法 | |
CN108354864B (zh) | 一种具有美白保湿功效的乳液的制备方法 | |
EP0949919B1 (en) | A process for stabilizing levogyre ascorbic acid (laa) and stable laa compositions | |
CN111166694A (zh) | 一种舒缓修护保湿面膜液及其制备方法 | |
CN112970787A (zh) | 一种八角茴香植物防腐抑菌组合物及其制备工艺与应用 | |
CN111557862A (zh) | 一种医用重组人源胶原蛋白及其制造方法 | |
CN106581741A (zh) | 一种重组人源胶原蛋白敷料及其制备方法 | |
CN116284495A (zh) | 全反式维甲酸低分子透明质酸酯衍生物及其制备方法和应用 | |
KR102381645B1 (ko) | 복령발효추출물을 포함하는 화장료 조성물 | |
CN114869829A (zh) | 一种舒缓霜及其制备方法 | |
CN115670968A (zh) | 一种具有抗炎舒敏作用的组合物、日化品 | |
CN111991316B (zh) | 防敏修复组合物及其制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210903 |